Severe weight loss after withdrawal of chronic pizotifen treatment

July 1998
Journal of Neurology, Neurosurgery & Psychiatry;Jul1998, Vol. 65 Issue 1, p137
Academic Journal
case study
No abstract available.


Related Articles

  • Oxandrolone may help thwart involuntary weight loss. Cerrato, Paul L. // RN;Mar96, Vol. 59 Issue 3, p71 

    States that for the weight loss that accompanies extensive surgery, chronic infections and severe trauma, Oxandrolone (Oxandrin) is available as a treatment. Recommended doses.

  • Weight variations in the prophylactic therapy of primary headaches: 6–month follow–up. Maggioni, Ferdinando; Ruffatti, Silvia; Dainese, Filippo; Mainardi, Federico; Zanchin, Giorgio // Journal of Headache & Pain;Sep2005, Vol. 6 Issue 4, p322 

    We conducted a study on 367 patients (86% female, 14% male; mean age 37±15 years) suffering from migraine with and without aura and chronic tension–type headache to evaluate the incidence of weight gain, an undesirable side effect observed during prophylactic therapy in primary...

  • Marked Weight Loss in a Type 2 Diabetic Patient Treated With Acarbose. Yoo, Wan-Hee; Park, Tae-Sun; Baek, Hong-Sun // Diabetes Care;Apr99, Vol. 22 Issue 4, p645 

    Focuses on a case report of a type 2 diabetic patient who experienced weight loss during about six months period of acarbose treatment and who regained weight after withdrawal. Historical and medical background of the patient; Effects of acarbose on body weight in diabetic patient; Possible...

  • Weight Loss Maintenance in Severely Obese Adults after an Intensive Lifestyle Intervention: 2- to 4-Year Follow-Up. Christiansen, Tore; Bruun, Jens M.; Madsen, Erik L.; Richelsen, Bj�rn // Obesity (19307381);Feb2007, Vol. 15 Issue 2, p413 

    The article presents research which dealt with weight loss maintenance in severely obese adults after an intensive lifestyle intervention. The researchers of the study highlight that obesity is a chronic health condition that needs additional strategies after a weight loss intervention in the...

  • Pizotifen in migraine prevention: A comparison with sodium valproate. Chitsaz, Ahmad; Reza Najafi, Mohammad; Aghapour Zangeneh, Foroud; Norouzi, Rasul; Salari, Mehri // Neurology Asia;Dec2012, Vol. 17 Issue 4, p319 

    Background & Objective: Pizotifen is an alternative option for prophylactic treatment of migraine headache. This study aims to compare the efficacy and safety of pizotifen with sodium valproate; one of the most-widely used drugs in migraine prevention. Methods: This was a single blind,...

  • Measuring weight and height — some potential practical problems. Stephan Rö, ssner // International Journal of Obesity & Related Metabolic Disorders;Nov1998, Vol. 22 Issue 11, p1136 

    Focuses on several problems encountered in measuring weight in relation to height. Result of improved self-esteem after weight loss; Impact of weight loss in treatment of obesity on height; Measurement of height in obesity clinics.

  • When patients have had enough. Singer, Karl // Patient Care;Oct2004, Vol. 38 Issue 10, p72 

    Describes cases of two chronically ill aged patients who decided to withdraw all of their medications and made appropriate judgment concerning their deaths. Treatment undertaken by the patient who had uncontrolled blood pressure; Diagnosis of the patient with weight loss and abdominal pain.

  • Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. Verschueren, P.; Vandooren, A. K.; Westhovens, R. // Clinical Rheumatology;Feb2005, Vol. 24 Issue 1, p87 

    Diarrhoea and weight loss are frequently reported adverse events in rheumatoid arthritis (RA) patients receiving the disease-modifying antirheumatic drug (DMARD) leflunomide. According to the available literature these side effects occur mostly during the first 6 months of treatment, are rather...

  • Osteoporotic Characteristics Persist in the Spine of Ovariectomized Sheep afterWithdrawal of Corticosteroid Administration. Zarrinkalam, Mohammad-Reza; Schultz, Christopher G.; Parkinson, Ian H.; Moore, Robert J. // Journal of Osteoporosis;2012, p1 

    A validated ovine model of osteoporosis achieves severe bone loss in a relatively short period. This study investigated if osteoporotic features persist in this model after cessation of corticosteroid administration. Methods. Osteoporosis was induced in nine ewes by chronic corticosteroid...

  • Peginterferon-α-2a/ribavirin.  // Reactions Weekly;6/1/2013, Issue 1455, p28 

    The article describes the case of a 25-year-old male patient who developed fatigue, weight loss, neutropenia and anemia after receiving peginterferon-α-2a for the treatment of chronic hepatitis C.


Read the Article


Sign out of this library

Other Topics